Roivant's Brepocitinib Meets Primary Endpoint in Both Phase 3 Uveitis Trials

• Roivant and Priovant announced positive Phase 3 CLARITY-1 and CLARITY-2 results for brepocitinib in non-infectious uveitis on October 21, 2026.
• Brepocitinib outperformed placebo on the primary endpoint and all key secondary endpoints, improving disease control without steroids and visual functioning.
• Safety findings were consistent with prior trials, with no new safety signals.
• Priovant plans to submit a supplemental New Drug Application for the indication in the first half of 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Roivant Sciences Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610210700PRIMZONEFULLFEED9850123) on October 21, 2026, and is solely responsible for the information contained therein.